Board of Directors

The Board of Directors consists of each of the three co-founders (Martin, Knighton, and Jeffery F. Miller) and Dr. Barbosa, who was elected to the board in 2018.

Miguel Barbosa

Miguel holds a PhD in viral oncology from University of California, Los Angeles and a B.S., in Genetics from the University of California, Davis. Former CSO Assembly Biosciences (2016 – 2017), Executive VP & CSO Mirna Therapeutics (2015-2016), VP and Head of Immunology Research & External Innovation Janssen (2010-2015), VP Discovery Research Johnson & Johnson (2005-2009).  Vivante Health Board member and SAB member of Aro Biotherapeutics.

James L. Knighton

MBA, Wharton School of Business, MS. Genetics, University of Pennsylvania; R&D, marketing and finance at the following companies: DuPont/DuPont Merck (1985-1994), Chiron (1994-1998), Sugen – CFO (1998-1999) and Caliper Life Sciences, President (1999-2004).

David W. Martin, MD

Duke Medical School; Professor of Medicine and Biochemistry, UCSF and Investigator, Howard Hughes Medical Institute; SVP of R&D at Genentech (1982-1990); Executive VP of R&D at DuPont Merck (1991-1993); President, Chiron Therapeutics (1994-1995) and founder and CEO of Eos Biotechnology (1997-2003).

Jeffery F. Miller, Ph.D.

Pylum’s third co-founder, is consultant and chairman of the company’s Scientific Advisory Board. Currently, Dr. Miller is M. Philip Davis Chair of the Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine at UCLA. His Ph.D. is from Tufts University School of Medicine, and his postdoctoral experience was at Stanford University School of Medicine with Professors Stanley Falkow and Lucy Tompkins.